Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02999269 · ClinicalTrials.gov registry record · Phase 4
ECT Pulse Amplitude and Medial Temporal Lobe Engagement
A Phase 4 study, sponsored by University of New Mexico.
- Completed
- Registry status
- Phase 4
- Development phase
- 62
- Enrollment target
NCT02999269 is a Phase 4 study that has completed, run by University of New Mexico. The registered enrollment target is 62 participants.
The verdict
NCT02999269, a Phase 4 study, has completed, sponsored by University of New Mexico.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 62 participants
- Enrollment target
Study Summary
Electroconvulsive therapy (ECT) remains the gold-standard treatment for patients with depressive episodes. During a typical four-week ECT series, most depressive episodes will respond to treatment and people will improve their level of functioning (return to work or family). Independent of the antidepressant effect of ECT, many patients experience transient memory impairment. This investigation will examine the impact of one ECT parameter (pulse amplitude or current) on brain changes (structure of connections within the brain) and clinical outcomes. The goal of this investigation is to determine the optimal parameter for an individual patient that will maintain the clinical response (reduce depression severity) and minimize side effects (eliminate memory issues related to treatment).
Interventions
- DEVICE MECTA Spectrum 5000Q Amplitude
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 62 participants |
| Start Date | 2016-10 |
| Est. Completion | 2020-03-23 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02999269
The ClinicalTrials.gov registry entry for NCT02999269 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 62 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of New Mexico, which has 168 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which MECTA Spectrum 5000Q Amplitude is the first listed.
NCT02999269 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02999269 about?
NCT02999269 is a clinical study titled "ECT Pulse Amplitude and Medial Temporal Lobe Engagement". Electroconvulsive therapy (ECT) remains the gold-standard treatment for patients with depressive episodes. During a typical four-week ECT series, most depressive episodes will respond to treatment and people will improve their level of functioning (return to work or family). Independent of the antid...
What is the current status of trial NCT02999269?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 62 participants. The study started on 2016-10. Estimated completion is 2020-03-23.
What interventions are being tested in trial NCT02999269?
The interventions under investigation include: MECTA Spectrum 5000Q Amplitude (DEVICE).
Who is sponsoring clinical trial NCT02999269?
This trial is sponsored by University of New Mexico, which has 168 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.